… $0.8 million in Q1 2024 Cash position strengthened … 3, 2025. “Our first-quarter performance demonstrates consistent execution of … . Capital expenditures amounted to $34 in the first quarter of fiscal … ,000 grocery stores and pharmacies, over 1,500 convenience …

… 18.2-18.5% in Q1 FY2026, following the sequential … ICRA expects the private capital expenditure (capex) cycle to remain measured … report stable revenue growth in Q1 FY2026 supported by resilient … levels (IT, FMCG and pharmaceuticals), improved on a YoY basis …

… 2024 and for the first quarter of 2025, respectively. … About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a … financial performance and projected expenditures; Supernus’ ability to … future collaborations with pharmaceutical companies and academic …

… -18.5 per cent in Q1 (April-June) of FY2026, … global environment, the private capital expenditure (capex) cycle is expected to … report stable revenue growth in Q1 FY2026, supported by resilient … levels (IT, FMCG and pharmaceuticals), improved on a YoY basis …

Caris Life Sciences, which specialises in the use of artificial intelligence to guide disease diagnosis, treatment selection, and patient monitoring, has raised the target price for its planned initial public offering (IPO), seeking to raise up to $471 …

… first quarter of fiscal year 2025 ended May 4, 2025. Fiscal Q1 … ET. Chewy Fiscal First Quarter 2025 Financial Results … flows from investing activities       Capital expenditures   (37.7 )     ( … new fulfillment centers, pharmacy facilities, veterinary clinics, …

… production, and government capital expenditure.   BT: Considering … and Pharmaceuticals: The healthcare and pharmaceutical sectors are … commencing in the first quarter of fiscal year … banking, insurance, telecommunications, pharmaceuticals, and cement, are …

… is expected to report its first-quarter financial results next week. Customer … 11% for the long term. Q1 Report on Tap The company … FY25. The target for capital expenditures is in the $3.6 … shoppers. The company’s thriving pharmacy business and steady growth of …

… items, which positively impacted first quarter 2024, adjusted EBITDA … for Q1 2025 was approximately 21%. In the first quarter, we … .7 million of capital expenditures. For the full year … while simultaneously enhancing our pharmacy business. Expansion is …

… methylation-based MRD assay. First Quarter 2025 Financial Results Revenues … . Revenue generated from pharma research and development services … services performed for our pharma customers, and several … ) a decrease in the expenditure for detection research and ( …